🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In a phase 2a study, 16 participants with APOL1 nephropathy received inaxaplin, an inhibitor of APOL1 channel function. Among 13 evaluable participants, the mean reduction in proteinuria was 47.6% at week 13. nej.md/3Te6NGr #nephrology #CKD

Just out - the spectrum of genetic disease in unselected adult kidney stone formers. Prevalence and characteristics of genetic disease in adult kidney stone formers academic.oup.com/ndt/article/do…

Thanks to everyone that contributed! Especially Eric Olinger john sayer Daniel G. Fuster Robert Geraghty and all the non-twitterorians like Matteo Bargagli & André Schaller. Special thanks also go to the patients and study personnel.

News from ERA from Young Nephrologists for Young Nephrologists - available from today onwards! ERA - European Renal Association YNP of ERA

ASCI members Krzysztof Kiryluk @kirylukk and Ali G. Gharavi Columbia University evaluate 3 cohorts and find monogenic kidney disorders are associated with an increased risk of kidney failure, higher eGFR decline rate, and lower rates of complete remission: buff.ly/3XBriRh

Study demonstrates polycystin-2 is a key regulator of cardiomyocyte’s ability to produce natriuretic peptides in mouse and human models and that loss of cardiac-specific polycystin-2 in the absence of kidney involvement results in elevated diastolic and systolic BP

Delighted to share our latest Greka Lab story in collaboration with Prof. Hao Wu on the molecular basis of TMED9 cargo receptor oligomerization and entrapment of misfolded cargo in the early secretory pathway. Broad Institute Harvard Medical School Mass General Brigham science.org/doi/10.1126/sc…

Great talk and great data!

Thanks for the great summary of our study! @KaitlinMayne YNP of ERA Hope we soon see more data on the influence of genetics on KSD !

Free scientific illustrations for biologists! 😍 NIH has released a library of 500+ free scientific illustrations to create figures, presentations, and illustrations! all freely available in the public domain. Retweet and spread the message! bioart.niaid.nih.gov

🚨 Dear all, do not miss this new KDIGO webinar series on NephroGenetics 🧬 ! Please do not hesitate to share, including amongst our younger colleagues ERA - European Renal Association SFNDT Filière ORKiD CJ Néphro YNP of ERA SNINephrologie

Core Curriculum by Abe Aron and Neera Dahl Clinical Genetic Testing in Nephrology: Core Curriculum 2024 bit.ly/4eZeSrS (FREE) Georgetown Nephrology Mayo Clinic Nephrology

Forget about GLP-1R agonists. Time to move to Boston. New data in Nature Metabolism shows that 1 hour of cold exposure with shivering for 10 consecutive days improves glucose tolerance and other metabolic health outcomes in humans with overweight or obesity.

What an exciting outcome for patients with kidney stones from our collaborative work in Bern ! Thanks go to all patients, study nurses and colleagues that participated and of course the mastermind Daniel G. Fuster !

Bonus. When a drug for diabetes significantly reduces kidney stones, results of a randomized trial of empagliflozin (Jardiance), a SGLT-2 inhibitor, in people without diabetes nature.com/articles/s4159… Nature Medicine Daniel G. Fuster Universität Bern

Hoffnungsvolle Berner Nierenstein-Nachrichten: Das Diabetesmedikament Empagliflozin reduzierte in der von #InselGruppe & Universität Bern geleiteten SWEETSTONE-Studie die Nierensteinbildung deutlich. Mehr: inselgruppe.ch/de/aktuell/det… Daniel G. Fuster Manuel Anderegg Faculty of Medicine, University of Bern

Low BMD and fractures are common in kidney stone formers. HCTZ up to 50 mg daily did not preserve BMD compared to placebo over 3 years. Hydrochlorothiazide and Bone Mineral Density in Patients... : Clinical Journal of the American Society of Nephrology journals.lww.com/cjasn/abstract…

Good news for the EMPASTONE trial - follow up of SWEETSTONE.